环磷腺苷葡胺联合莫雷西嗪对室性心律失常患者心率变异性及炎症因子的影响

Effects of Meglumine Cyclic Adenosine Monophosphate Combined with Moricizine on Heart Rate Variability and Inflammatory Factors in Patients with Ventricular Arrhythmia

目的观察分析环磷腺苷葡胺联合莫雷西嗪对室性心律失常患者心率变异性及炎症因子的影响。方法选取2019年6月—2020年5月该院收治的76例室性心律失常患者作为研究对象,按照数字随机表法分为观察组和对照组,每组38例。对照组单纯应用莫雷西嗪治疗,观察组应用莫雷西嗪联合环磷腺苷葡胺治疗。比较两组室性心律失常患者治疗前后的心率变异性指标水平、炎症因子水平以及临床治疗效果。结果治疗前,观察组SDANN值为(102.2±7.4)ms、SDNN值为(95.2±7.6)ms、RMSSD值为(21.4±4.8)ms,对照组分别为(103.1±7.1)、(95.5±7.2)、(21.5±4.7)ms,组间差异无统计学意义(P>0.05),治疗后,观察组SDANN值为(130.3±9.4)ms、SDNN值为(128.1±9.6)ms、RMSSD值为(34.6±5.4)ms,对照组分别为(113.5±9.6)、(111.7±9.2)、(27.6±5.1)ms,组间差异有统计学意义(t=12.157、20.307、28.953,P<0.05);治疗前,两组肿瘤坏死因子α、白细胞介素6、超敏C反应蛋白、B型利钠肽差异无统计学意义(P>0.05),治疗后观察组肿瘤坏死因子α为(9.1±1.1)μg/L、白细胞介素6为(6.4±1.3)ng/L、超敏C反应蛋白为(7.4±1.5)mg/L、B型利钠肽为(92.4±8.3)pg/mL,对照组分别为(15.6±1.4)μg/L、(9.7±1.5)ng/L、(13.6±1.6)mg/L、(115.5±8.7)pg/mL,组间差异有统计学意义(t=12.668、20.598、26.665、33.872,P<0.05);观察组室性心律失常患者的临床治疗效果明显高于对照组,差异有统计学意义(P<0.05)。结论环磷腺苷葡胺联合莫雷西嗪治疗室性心律失常患者能积极改善心率变异性指标,提高临床治疗效果,降低炎症因子水平。

Objective To observe and analyze the effects of meglumine cyclic adenosine monophosphate combined with moricizine on heart rate variability and inflammatory factors in patients with ventricular arrhythmia.Methods A total of 76 patients with ventricular arrhythmia admitted to the hospital from June 2019 to May 2020 were selected as the research objects.They were divided into the observation group and the control group according to the number random table method,with 38 cases in each group.The control group was treated with moricizine alone,and the observation group was treated with moricizine combined with meglumine cyclic adenosine monophosphate.The heart rate variability index levels,inflammatory factor levels and clinical treatment effects of the two groups of patients with ventricular arrhythmia before and after treatment were compared.Results Before treatment,the SDANN value of the observation group was(102.2±7.4)ms,the SDNN value was(95.2±7.6)ms,and the RMSSD value was(21.4±4.8)ms.The control group was(103.1±7.1)ms,(95.5±7.2)ms and(21.5±4.7)ms,respectively.there was no statistically significant difference between the groups(P>0.05).After treatment,the SDANN value of the observation group was(130.3±9.4)ms,the SDNN value was(128.1±9.6)ms,and the RMSSD value was(34.6±5.4)ms,the control group was(113.5±9.6)ms,(111.7±9.2)ms and(27.6±5.1)ms,the difference between groups was statistically significant(t=12.157,20.307,28.953,P<0.05).Before treatment,there was no statistically significant difference in tumor necrosis factorα,interleukin 6,high-sensitivity C-reactive protein,and B-type natriuretic peptide between the two groups(P>0.05).After treatment,the tumor necrosis factorαof the observation group was(9.1±1.1)μg/L,interleukin 6 was(6.4±1.3)ng/L,hypersensitivity C-reactive protein was(7.4±1.5)mg/L,B-type natriuretic peptide was(92.4±8.3)pg/mL,the control group were(15.6±1.4)μg/L,(9.7±1.5)ng/L,(13.6±1.6)mg/L,(115.5±8.7)pg/mL,the difference between groups was statistically significant(t=12.668,20.598,26.665,33.872,P<0.05);the clinical treatment effect of patients with ventricular arrhythmia in the observation group was significantly higher than that in the control group,and the difference was statistically significant(P<0.05).Conclusion The combination of meglumine cyclic adenosine phosphate and moricizine in the treatment of patients with ventricular arrhythmia can actively improve the index of heart rate variability,improve the clinical treatment effect,and reduce the level of inflammatory factors.